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We would like to thank Professor Perrin for his 
comments regarding the Libyan HIV-1 outbreak 
case [1,2]. The following is our response to the 
points made by Professor Perrin. We would like to 
divide our response in separate sections, for 
clarification. 
 
Vertical Transmission of HCV 
 Professor Perrin wrote the following comments 
[2]; “What we found is that all children were 
infected by a HIV-1 monophyletic recombinant 
circulating form from West Africa and 40 % of them 
were infected with HCV.  We excluded vertical 
transmission for both HIV and HCV on the basis of 
serology in parents. Thus the assumption on page 
2 of the viewpoint mentioning that HCV was 
acquired through vertical transmission is incorrect 
since most of the mothers were not infected.  The 
fact that we found clusters of four HCV genotypes 
reflect simply the fact that HCV is much more 
common in Libya than HIV-1, thus in the case of 
improper sterilisation procedures or reuse of 
contaminated needles it is expected to have 
different HCV genotypes.”………. “In western 
countries we have more or less controlled the 
propagation of HIV-1 infection in intravenous drug 
users but still observe frequently HCV infections in 
this population suggesting that transmissibility of 
HCV is higher than that of HIV-1.” 
If we take what the eminent professor stated in 
his comments that “transmissibility of HCV is 
higher than that of HIV-1,” then it will be 
impossible to have 100% of the children HIV-1 
positive but only 40% of the same children HCV 
positive. Obviously, according to the professor’s 
own words the statistics do not make any sense 
[3-6].  In our opinion, when epidemiological data 
do not add up the first rule is to look for something 
that may not be obvious (see below for further 
comments).    
As we stated in our original writing, the numbers 
do not add up. If we take the nosocomial infection 
and bad medical practices into account then one 
has to infect between 200,000 to several million 
children with contaminated needles (taking CDC’s 
rate of 0.3% -0.009%; [7-8]) for HIV-1 to be able to 
get 500+ children infected with the same 
monophyletic strain (see more clarification below: 
3-8). Obviously, the numbers do not add up. 
These numbers exceed the number of children, 
not only in Benghazi, but in the whole of Libya.  In 
our opinion the low rate of HCV and the more than 
2.5 times higher rate of HIV-1 in these children 
may indicate an intentional inoculation (see below 
for detail).  
 
Case of Monophyletic Virus 
  Let us look at this possibility. What is a 
statistical possibility that 500+ children carry the 
same monophyletic HIV-1 strain? Bear in mind 
that, according to all three scientific articles, it is a 
unique sequence that did not exist previously 
(CRF02-AG: [4-6]). What is the possibility that all 
the children carry the same monophyletic strain if 
the infection was initiated by a drug abuser at El-
Fatah children hospital and due to inappropriate 
infection control the contaminated needles were 
reused that spread HIV-1, HCV and HBV to more 
then 500 children? The possibility of this is close 
to zero and the western point regarding this issue 
is absolutely incorrect. Here are the reasons: 
a) Suppose one drug abuser from Sub-Saharan 
Africa with high viremia (carrying subtype CRF02-
AG) came to El-Fatah children hospital and 
someone drew his blood for some workup and 
then used the same needle that was used for 
drawing blood to inject a child for intravenous 
liquid containing blood products, antibiotics, 
nutrition or vitamin, etc. (Of course, one has to 
imagine a lot, because how a dirty needle from an 
adult ward of the hospital reached the paediatric 
general medicine unit is beyond logic, but for the 
sake of argument we take the scenario to be the 
case. In addition, if that is what really happened it 
would be considered a criminal act in any 
country). Now, assuming that that was possible 
and the dirty needle was reused to inject one child 
(our hypothetical index case) then one child would 
be infected with this one needle stick (even though 
the chance of it is 0.3%; [7-8]).  If the same needle 
were used for another child, then the second child 
would be safe from this HIV-1 subtype since the 
first injection will carry the viral particles to the 1st 
child’s body (intramuscular or intravenous route) 
and the needle will be clean of HIV after the 
injection (and that is clearly stated from the CDC 
risk assessment statement refs [7-8]). Now, one 
supposes that this child #1 got infected. Now, let 
us see what happens to this virus if we assume 
that the very first child did get infected with HIV-1 
subtype CRF02-AG. This virus will go through a 
series of replication events and in 3-6 weeks may 
develop a serious enough viremia with flu-like 
symptoms and mild fever (chance of that is also 
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less then 0.01%; [7-8]).  We assume that he was 
brought in to hospital for treatment of some sort 
(not for flu-like symptoms because they are 
generally very mild). But, suppose that this 
happened and he received injection for treatment 
and the needle that was used to treat him was also 
used to treat a second and third and fourth child 
the very same day.  The possibility is 1 in 333 that 
the second child may get infected but the 3rd and 
4th would be safe [7-8].  Now we repeat this same 
scenario again after 3-6 weeks when child #2 got 
infected and developed viremia high enough to be 
infectious by needle stick and a 3rd child got 
infected when a dirty needle from the child #2 was 
used to inject a 3rd child. Now in order to get 20 
children to be infected in this manner it would have 
taken about two years (an average of 6 weeks X 
20=120 weeks=~2 yrs).  The question is: would 
the virus remain monophyletic? The answer is 
absolutely not! (unless a cloned virus was used to 
infect each child). 
To elaborate on this we have to see how HIV-1 
replicates in the human body. Once inside the 
human body the virus seeks out CD4+ T cells and 
then the virus releases its two RNA genomes (it is 
diploid RNA retrovirus) inside the cytoplasm of the 
infected host cells [9-10]. This diploid RNA 
exchanges the genes right at the beginning, 
creating a new recombinant provirus [10]. During 
the ensuing replicative cycle, recombination 
between the two genomes would occur [9-12]. To 
the extent that the two RNA genomes will be 
distinct, recombination viral cDNAs coding for 
genetic information different from that of the two 
parental diploid RNAs [10-11, 13-14]. Numerous 
studies performed in vitro have documented the 
occurrence of recombination during HIV-1 
replication [15]. Although these studies have found 
that the rate of recombination can be influenced by 
the nature of the target cell and that certain 
genomic regions may be hot spots for 
recombination, there is general agreement that 
recombination occurs frequently throughout the 
genome (2 to 20 events/genome /replicative cycle) 
and has the capacity to rapidly shuffle genomic 
segments from parental viruses [10-12, 14-18]. 
Numerous viral strains derived through 
recombination between distinct HIV-1 subtypes 
have been identified in infected individuals, 
indicating that recombination also occurs in vivo 
[18-20], and studies performed using limiting-
dilution-PCR assays suggest that such events 
occur  very frequently [9, 21-22].  So, in the 
Western case scenario, the first child (the 
hypothetical index case) once infected with a 
single viral subtype would be expressing 
thousands of new recombinant quasispecies [23-
24]. And by the time he goes to the hospital again 
for whatever reason after 6 weeks he would have 
different HIVs and multiple subtypes (and not the 
original parental one; [9-23]).  So, the presence of 
monophyletic virus is one of the keys to the 
mystery! It is becoming apparent from this 
discussion that it is very unlikely the virus 
originated from a single human being and spread 
to 500+ children in a short time period by the 
nosocomial infection, regardless of how 
inappropriate the infection control unit was. One 
can see this kind of scenario all over the 
developing nations and, yet, no one has 
encountered the kind of outbreak that is described 
in El-Fatah children hospital [3-6].  The alternate 
explanation is that the children were infected with 
two cloned HIV-1 viruses (first with an attenuated 
HIV-1 and then with a pathogenic strain of HIV-1).  
We will explain this shortly.    
b) Now, let us look at the assumption that the 
African drug abuser who came to El-Fatah 
children hospital was carrying a single HIV 
subtype. This assumption is also false. No living 
human being infected with HIV-1 carries a single 
HIV-1 subtype. There are hundreds of subtypes in 
a single human being at all times [20-23].   
c) Is it possible that a monophyletic strain can 
be maintained for a long time in vivo? If we accept 
the scenario that the hypothetical index case 
maintained a single subtype: CRF02-AG and it 
then spread to the next child due to nosocomial 
infection and the next and so forth. However, in 
reality, the 2nd child cannot maintain the same 
subtype due to multiple recombination events that 
are so innate to retroviruses and HIV-1 [9-24]. If 
we assume for a second that this truly aberrant 
subtype was able to maintain its integrity through 
several children it could not do so for so many 
years and in so many children with genetically 
different hosts [9-24]. The advantages that are 
acquired through recombination and the impact of 
recombination on HIV-1 pathogenesis in individual 
patients appear to be essential for viral survival 
[23-24]. The shuffling of polymorphisms found in 
distinct viral quasispecies plays a crucial role in 
generating viral diversity and genetic-based 
resistance for viruses in genetically and 
immunologically different hosts [9-23]. The ability 
to maintain extensive diversity is extremely 
important for viral pathogenesis and survival, 
because it ensures the availability of viral 
quasispecies that are able to escape changes in 
the selective pressures exerted by the immune 
response or by antiretroviral therapy. Indeed, 
results obtained with other models support the 
idea that diversity generated by recombination is 
necessary for adaptation to changing evolutionary 
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pressures [21-23] and this is one of the major 
reasons that we are unable to develop an effective 
vaccine against HIV-1 (reviewed in [25]).   
d) From the above discussion it must be clear 
that if a single HIV-1 infected child was admitted a 
number of times within 1-2 years and he or she 
served as the index case, that individual would not 
be able to maintain the same viral subtype for that 
long and may transmit different quasispecies to 
different children [9-23]. These subtypes will 
further recombine into the new hosts and 
therefore, it is highly unlikely that the virus will 
remain monophyletic [4-6]. 
e) It is one thing that a group of drug addicts 
spent 24-48 hours together and exchanged a dirty 
needle and received a single predominant 
subtype. It is entirely another thing if 400+ children 
got infected over a long period of time and showed 
a monophyletic subtype years after exposure [4-6].  
 
Case of unsafe medical practices and reuse of 
unsterilized needles 
One of the most important points that we have to 
take under consideration is that maybe the 
children were infected due to reuse of unsterilized 
needles.  It is possible that due to years of 
sanctions the Libyan Government was unable to 
provide sufficient number of sterilized needles and 
reuse of blood laden needles served as the main 
source of epidemic [3-6]. However, several 
credible reports refute this theory (reviewed in [24-
25). A recent report by Priddy et al [24] has shown 
that such practices do not result in HIV 
transmission. This group investigated the potential 
medical transmission of HIV through unsafe 
medical injections in 16 rural health institutions in 
Ethiopia (where HIV-1 is an epidemic). Most 
institutions reported re-using disposable 
needle/syringes, and 12% of observed injections 
were given with used, disposable syringes 
prepared for re-use. Analysis of used needle 
flushes showed no HIV RNA. These investigators 
concluded that despite the re-use of disposable 
needles, medical injection practices are not likely 
to contribute significantly to HIV transmission in 
this region. Unsafe needle sticks and intravenous 
injections from used needles and syringes are very 
common and they generally result in HCV and 
HBV transmission but rarely in HIV. This particular 
question was investigated by the World Health 
Organization Investigators.  Therefore, Hutin et al 
[25] have described the injection practices 
worldwide in terms of frequency and safety. The 
WHO defined the global burden of disease into 14 
regions on the basis of geography and mortality 
patterns. Their data sources included published 
studies and unpublished WHO reports. Studies 
were reviewed by using a standardized decision 
making algorithm to generate region specific 
estimates. They included both formal and informal 
healthcare facilities. They showed that the annual 
number of injections per person and proportion of 
injections administered with syringes or needles, 
or both, are being reused in the absence of 
sterilization in the majority of the developing 
nations. The analysis excluded four regions 
(predominantly affluent, developed nations) where 
reuse of injection equipment in the absence of 
sterilization was assumed to be negligible. In the 
10 other regions, the annual ratio of injections per 
person ranged from 1.7 to 11.3. Of these, the 
proportion administered with equipment reused in 
the absence of sterilization ranged from 1.2% to 
75.0%. Reuse was highest in the South East Asia 
region (seven countries in South East Asia), the 
eastern Mediterranean region (nine countries, 
mostly located in the Middle East crescent), and 
the western Pacific region (22 countries). No 
information regarding injection safety was 
available for Latin America. They concluded that 
overuse of injections and unsafe practices are still 
common in developing and transitional countries 
[25]. Obviously, if reuse of injectable needles or 
syringes were the main culprits this problem would 
have been more common in India or China or 
other poor African nations where the numbers of 
HIV-1 infected individuals are much higher or 
where the populations are more dense. Of note, in 
the case of El-Fatah Children’s Hospital the 
problem was associated with only one unit 
(General Medical Unit) and not other units like the 
hematology/ oncology, the renal dialysis, and the 
neonatal units, which are more likely to have such 
risk from the nosocomial point of view [3-6].  
 
 Western Scientists’ Mistakes 
As it is summarized in the above scientific 
discussion, the possibility of the HIV-1 outbreak in 
the Libyan children is virtually impossible to have 
occurred by the nosocomial route. Therefore, it 
was essential to carry out more extensive 
investigation. As you might have noticed none of 
the research articles reports a thorough and solid 
scientific investigation. The first thing that would 
have occurred to the curious minds would be to 
sequence the full length HIV-1 instead of carrying 
out the sequence analyses of a short gag 
sequence [4-6]. If such an incident had happened 
in any of the Western countries the world would be 
up in arms to figure out what is behind the 
outbreak.  The case of a dentist in the USA who 
apparently infected his patients with HIV-1 is a 
glaring example of this situation [7]. The ELISA 
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and Western blot analysis reported by Professor 
Perrin is simply not sufficient to address the issue. 
The second question that would have occurred 
to us is to entertain the possibility of an intentional 
infection!  We will discuss this below.  
 
Mistake with dating the HIV-1 
It is concluded by several investigators that the 
subtype CRF02-AG in question existed in Africa 
before and it was dated back to 1994-95. That is 
incorrect [6].   It is one thing to have a material 
evidence of one of the patients’ blood from 1994-
95 that was HIV-1 positive. It is entirely different to 
calculate such dates from the small fragments of 
HIV-1 sequences that were isolated several years 
later by mathematical formulas that are inadequate 
[4-6]. The dating of HIV-1 by utilizing Bayesian 
algorithm has been challenged and dates for 
retrovirus and especially HIV-1 by any currently 
existing methods based on Bayesian logic are 
incorrect [28-30]. This type of analysis has been 
tried for dating the Origin of HIV-1 [29]. Meyerhans 
et al [29] and many others have reported evidence 
of "massive" recombination in HIV-1 [9-23, 26]. 
The rate of recombination in HIV-1 is several 
orders of magnitudes higher than the rate of 
"point-substitution" (i.e. normal single base-pair 
mutation is one in a million). Ignoring 
recombination, they estimate, would lead to gross 
overestimation of the age of the HIV-1 by using the 
phylogenetic dating approach that has been used 
for Origin of HIV-1.   Schierup et al [28] have gone 
much further than that, for they called the whole 
basis of phylogenetic dating for HIV-1 by Bayesian 
method into question [28-30]. In many 
investigators’ opinion it is not valid to use a 
phylogenetic method to obtain the time estimate 
for HIV-1. They are further stating that such early 
recombination [10] would mean that phylogenetic 
dating theory is inherently flawed, and should not 
be used to date HIV-1 [28-30]. Therefore, the 
article that concluded that the OUTBREAK viral 
subtype existed in 1994-95 is of dubious value due 
to unsound scientific reasoning [6, 9-23].   
 
What might have occurred and what makes 
scientific sense 
It is time for us to face the scientific facts. From 
the scientific data described in the preceding 
sections it makes more sense to explore the 
possibility that the children were part of some sort 
of scientific experimentation. We have several 
unsolved issues that cannot be explained by the 
nosocomial hypothesis: i) unusually high rate of 
infection, ii) presence of HCV in 40% and HIV-1 in 
100%, presence of four HCV genotypes but only 
one monophyletic HIV-1, iii) presence of unusual 
HBV antibodies, iv) presence of monophyletic 
subtype [3-6], and v) presence of a unique HIV-1 
subtype that is refusing to change its genetic 
makeup after  housing in the bodies of close to 
600 children after almost a decade [9-23]. 
 
Which hypothesis makes sense? 
In the mid to late 1990s, there was a strong 
conviction amongst the top western scientists that 
an attenuated live HIV-1 vaccine could be used to 
prevent HIV-1 spread [reviewed in 25, 30-37]. For 
example, it was shown that if macaques were 
exposed to a nef deleted mutant SIV first and then 
infected with a wild type pathogenic SIV strain 
they were protected from the pathogenic strain of 
SIV-1. Similarly, Baba et al [31] have reported that 
an attenuated SIV, designated SIVdelta3 (a 
mutant of SIV deleted in the nef and Vpr genes), 
induced a lethal AIDS-like disease in two of the 
four macaque neonates infected orally, but the 
infection remained attenuated in the adult after 
intravenous infection [31, 33]. Deacon et al [32] 
reported that the six recipients of blood or blood 
products from a single HIV-1-infected donor had 
remained free of HIV-1-related disease after 10-14 
years. This HIV-1 isolate from this donor was 
found to be defective at the nef gene, very similar 
to SIVdelta3 described above [34, 37]. Therefore, 
it would be logical to assume that the HIV-
vaccinologists were looking for a place where they 
could carry out a secret attenuated delta nef HIV-1 
vaccine trial. We are not implying that the same 
scientists were involved in any way but someone 
in the corporate world might have decided to do 
so. 
 
So why Libya? 
Between 1997 and 1999 Libya was one of the 
few countries that were free from HIV-1 infection. 
It was isolated from the Western world due to 
sanctions. It was ridiculed by the West.  If a 
clinical trial was carried out in Sub-Saharan Africa 
the results would have been doubtful due to high 
infection rate in this part of the world. 
 
 Why children? 
As mentioned above, in AIDS models the 
attenuated live mutant of SIV was protective in 
adults but not in neonates [33-38]. A triple mutant 
was constructed in 1997-98 that was shown to be 
safer in neonate macaques [33]. We strongly 
suspect that a HIV-1 equivalent of the delta nef 
attenuated mutant was used to experiment on 
these children. The underlying assumption would 
be that if the trial vaccine failed then the Western 
Media could then blame the incident on the 
craziness of the Libyan Leader, incompetency of 
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the infection control unit, and discredit the whole 
event. That is exactly what is happening now 
[reviewed in 3]. The Western media are full of 
comments from top vaccinologists and even Noble 
Laureates that are seeking justice in Libya. One 
cannot always believe what a Noble Laureate 
claims.  Since, there is one Noble Laureate who 
claimed that HIV-1 is not the cause of AIDS [40]. 
However, it is amazing that no one from the other 
side is being allowed by the same top journals to 
speak on behalf of the Libyan children, 56 of 
whom already have died and the rest may also die 
from this illness. If it is the result of an experiment 
it needs urgent attention. Why are Western 
scientists refusing to even consider the possibility 
of looking into this matter? It has been almost a 
decade since the incident was first exposed. Why 
is it that after a decade the investigation into 
possible scientific misconduct has not been carried 
out? 
Therefore, we argue, that a team might have 
been assembled in 1997-98 to try a new live 
attenuated vaccine in the part of the globe where 
this kind of human experimentation would go 
unnoticed. Certainly, the political climate, the total 
isolation of Libya and the tribal nature of Libyan 
people in Benghazi might have played important 
roles. Therefore, if the sinister plan was 
discovered it would be deniable. So we suggest 
that maybe what is happening, and that these 
eminent Italian, Swiss and French scientists may 
be just used as innocent pawns in this game most 
likely carried out by some corporate vaccine 
maker.   
 
Possible Nature of Experimentation 
  We believe that children were divided into three 
groups; one as positive control, infected with the 
cloned pathogenic virus, a second group with the 
attenuated virus and third (the largest most likely > 
200 children) were the real experimental vaccine 
group. If we look at all the live attenuated vaccine 
trials in macaques we will see the similar three 
group pattern. The so-called vaccine was most 
likely stored in human serum bottles (that may 
explain HCV and HBV positive infections and 
unusual antibodies to HBV). Group one received 
live pathogenic virus (the children that became 
sick in a few months and showed very high levels 
of viremias). The second group may exhibit 
relatively lower viremia or alternatively the 
attenuated virus may be more pathogenic than 
was expected. And the third initially received a nef 
deleted attenuated HIV-1. After six months or so, 
the same children (the 3rd group) were given a full 
length pathogenic virus to monitor the potential 
protective effect of the attenuated putative 
vaccine. This largest group would have shown 
very high viremias if the attenuated vaccine failed. 
If we are correct then the experiment in reality is 
still in progress and these children are still 
experimental subjects as far as the trial goes.   
Certainly this would be shocking, and therefore 
our fellow scientists and colleagues would not 
wish to believe that this might have happened! 
Yet, have they ruled out all the possibilities? The 
answer is no. 
Just to give a few examples of the current affair 
of scientific experimentation. Where are the 
infamous circumcision trials being conducted? In 
the poor nations of Africa or Asia! Where was the 
original live attenuated polio vaccine trials carried 
out?  In Africa! Where are the majority of the 
current anti-retroviral drug trials being carried out? 
In Africa or Asia! Why then would it be such a 
surprise to anyone that such a human 
experimental trial might have occurred in Libya?  
  
What is the next step?  How do we find the 
truth? 
Very simple. If our assessment is correct then all 
we have to do is to isolate PBMCs (CD4+ T 
lymphocytes) and separate them into single cells 
and culture each single cell into separate wells 
and stimulate them with PHA. If there was an 
attenuated mutant used for experiments, we 
should be able to find it in a small fraction of cells 
(i.e. 1 in 1,000 CD4+) latently infected cells 
[reviewed in 39]. These latent cells should still 
carry any experimental attenuated HIV-1 that was 
used. As we know nef deletion does not often 
happen naturally, therefore, a full length 
sequencing of HIV from 300+ children would go 
far in addressing the issue. A full length 
sequencing of the stimulated CD4+ cells even 
from a small group of relatively healthy children 
with low viral load may prove to be very useful in 
solving the issue at hand.   
 
References 
1.  Bagasra O, Alsayari M. The case of the 
Libyan HIV-1 Outbreak. Libyan J Med, 2007:2 (1). 
AOP: 070201.  
2.  Perrin L. More than 30% HCV prevalence 
in the HIV-1 El-Fateh children hospital outbreak is 
a key for both elucidation and public health 
measures. Libyan J Med, 2007.2(2). AOP:070219. 
3.  Rosenthal E.  HIV injustice in Libya--
Scapegoating foreign medical professionals. N 
Engl J Med.  2006, 355:2505-8.  
4.  Yerly S, Quadri R, Negro F, Barbe KP, 
Cheseaux JJ, Burgisser P, Siegrist CA, Perrin L. 
Nosocomial outbreak of multiple bloodborne viral 
infections. J Infect Dis 2001;184:369-72.  
Page 60   





  Libyan J Med, AOP: 070221
 
5.  Visco-Comandini U, Cappiello G, Liuzzi G, 
Tozzi V, Anzidei G, Abbate I, Amendola A, Bordi L, 
Budabbus MA, Eljhawi OA, Mehabresh MI, Girardi 
E, Antinori A, Capobianchi MR, Sonnerborg A, 
Ippolito G; Libya Project Task Force. Monophyletic 
HIV type 1 CRF02-AG in a nosocomial outbreak in 
Benghazi, Libya. AIDS Res Hum Retroviruses 
2002;18:727-32.  
6.  de Oliveira T, Pybus OG, Rambaut A, 
Salemi M, Cassol S, Ciccozzi M, Rezza G, 
Gattinara GC, D'Arrigo R, Amicosante M, Perrin L, 
Colizzi V, Perno CF; Benghazi Study 
Group.Molecular epidemiology: HIV-1 and HCV 
sequences from Libyan outbreak. Nature. 2006; 
444:836-7.  
7.  CDC. Updated U.S. Public Health Service 
guidelines for the management of occupational 
exposures to HBV, HCV, and HIV and 
recommendations for postexposure prophylaxis. 
MMWR 2001;50 (No. RR-11):1--52.  
8.  Cardo DM, Culver DH, Ciesielski CA, 
Srivastava PU, Marcus R, Abiteboul D, Heptonstall 
J, Ippolito G, Lot F, McKibben PS, Bell DM. A 
case-control study of HIV seroconversion in health 
care workers after percutaneous exposure. 
Centers for Disease Control and Prevention 
Needlestick Surveillance Group. N Engl J Med. 
1997 Nov 20;337(21):1485-90.  
9.  Charpentier C, Nora T, Tenaillon O, Clavel 
F, Hance AJ. Extensive recombination among 
human immunodeficiency virus type 1 
quasispecies makes an important contribution to 
viral diversity in individual patients. J Virol. 2006; 
80:2472-82. 
10.  Paillart, J. C., M. Shehu-Xhilaga, R. 
Marquet, and J. Mak. Dimerization of retroviral 
RNA genomes: an inseparable pair. Nat. Rev. 
Microbiol. 2004; 2:461-472.  
11.  Boone, L. R., and A. M. Skalka. Viral DNA 
synthesized in vitro by avian retrovirus particles 
permeabilized with melittin. II. Evidence for a 
strand displacement mechanism in plus-strand 
synthesis. J. Virol. 1981; 37:117-126.  
12.  Coffin, J. M. Structure, replication, and 
recombination of retrovirus genomes: some 
unifying hypotheses. J. Gen. Virol. 1979; 42:1-26.  
13.  Chen J, Dang Q, Unutmaz D, Pathak VK, 
Maldarelli F, Powell D, Hu WS.  Mechanisms of 
nonrandom human immunodeficiency virus type 1 
infection and double infection: preference in virus 
entry is important but is not the sole factor. J. Virol. 
2005;79:4140-4149.   
14.  Magiorkinis G,Paraskevis D, Vandamme 
AM,Magiorkinis E,Sypsa V, Hatzakis A.  In vivo 
characteristics of human immunodeficiency virus 
type 1 intersubtype recombination: determination 
of hot spots and correlation with sequence 
similarity. J. Gen. Virol. 2003; 84:2715-2722.  
15.  Shriner D, Rodrigo AG, Nickle DC,Mullins 
JI. Pervasive genomic recombination of HIV-1 in 
vivo. Genetics 2004; 167:1573-1583.   
16. Zhuang J, Jetzt AE, Sun G,Yu 
H,Klarmann G,Ron Y,Preston BD,Dougherty JP.   
Human immunodeficiency virus type 1 
recombination: rate, fidelity, and putative hot 
spots. J. Virol. 2002; 76:11273-11282.   
17.  Jetzt AE, Yu H, Klarmann GJ, Ron Y, 
Preston BD, Dougherty JP.High rate of 
recombination throughout the human 
immunodeficiency virus type 1 genome. J. Virol. 
2000; 74:1234-1240.   
18.  Levy DN, Aldrovandi GM, Kutsch O, Shaw 
GM. Dynamics of HIV-1 recombination in its 
natural target cells. Proc. Natl. Acad. Sci. USA 
2004; 101:4204-4209. 
19.  Nikolenko GN, Svarovskaia ES, Delviks 
KA, Pathak VK.  Antiretroviral drug resistance 
mutations in human immunodeficiency virus type 1 
reverse transcriptase increase template-switching 
frequency. J. Virol. 2004; 78:8761-8770.  
20. Onafuwa A, An W, Robson ND, 
Telesnitsky A.  Human immunodeficiency virus 
type 1 genetic recombination is more frequent 
than that of Moloney murine leukemia virus 
despite similar template switching rates. J. Virol. 
2003; 77:4577-4587.  
21.  Otto, S. P., and T. Lenormand.  Resolving 
the paradox of sex and recombination. Nat. Rev. 
Genet. 2002; 3:252-261.  
22.  Rhodes TD, Nikolaitchik O, Chen J, 
Powell D, Hu WS.  Genetic recombination of 
human immunodeficiency virus type 1 in one 
round of viral replication: effects of genetic 
distance, target cells, accessory genes, and lack 
of high negative interference in crossover events. 
J. Virol. 2005; 79:1666-1677.   
23.  Moutouh, L., J. Corbeil, and D. D. 
Richman. Recombination leads to the rapid 
emergence of HIV-1 dually resistant mutants 
under selective drug pressure. Proc. Natl. Acad. 
Sci. USA 1996; 93:6106-6111.   
24.  Priddy F, et al . Potential for medical 
transmission of HIV in Ethiopia. AIDS. 
2006;20:133-35. 
25.  Hutin YJ, Hauri AM, Armstrong GL. Use of 
injections in healthcare settings worldwide, 2000: 
literature review and regional estimates. : BMJ. 
2003;327(7423):1075. 
26.  Goddard, M. R., H. C. Godfray, and A. 
Burt. Sex increases the efficacy of natural 
selection in experimental yeast populations. 
Nature 2000; 434:636-640.  
Page 61   





  Libyan J Med, AOP: 070221
 
27.  Bagasra O. HIV and Molecular Immunity: 
Prospect for AIDS Vaccine.  Eaton publishing, 
(March 1999. Natic, MA. USA.  
28.  Schierup MH, Hein J. Recombination and 
the molecular clock. Mol Biol Evol. 
2000:17(10):1578-9. 
29.  Meyerhans A, Jung A, Maier R, Vartanian 
JP, Bocharov G, Wain-Hobson S.  The non-clonal 
and transitory nature of HIV in vivo. Swiss Med 
Wkly. 2003; 133:451-4. 
30.  Suzuki Y, Glazko GV, Nei M. 
Overcredibility of molecular phylogenies obtained 
by Bayesian phylogenetics. PNAS 2002; 
99:16138-43  
31.  Baba TW, Jeong YS, Pennick D, Bronson 
R, Greene MF, Ruprecht RM. Pathogenicity of live 
attenuated SIV after mucosal infection of neonatal 
macaques. Science 1995; 267,1820-25.  
32.  Deacon NJ, Tsykin A, Solomon A, Smith 
K, Ludford-Menting M, Hooker DJ, McPhee DA, 
Greenway AL, Ellett A, Chatfield C, Lawson VA, 
Crowe S, Maerz A, Sonza S, Learmont J, Sullivan 
JS, Cunningham A, Dwyer D, Dowton D, Mills J.   
Genomic structure of an attenuated quasispecies 
of HIV-1 from a blood transfusion donor and 
recipients. Science 1995; 270, 988-91. 
33.  Desrosiers RC, Lifson JD,  Gibbs JS, 
Czajak SC, Howe AY, Arthur LO,Johnson RP.   
Identification of highly attenuated mutants of 
simian immunodeficiency virus. J Virol.1998; 
72:1431-7. 
34.  Chakrabarti L, et al.  Limited viral spread 
and rapid immune response in lymph nodes of 
macaques inoculated with attenuated simian 
immunodeficiency virus. Virology. 1995;213:535-
48. 
35.  Kirchhoff F, Greenough TC, Brettler DB, 
Sullivan JL, Desrosiers RC. Brief report: absence 
of intact nef sequences in a long-term survivor with 
nonprogressive HIV-1 infection.. N Engl J Med. 
1995;332:228-32.   
36.  Wyand MS, Manson KH, Lackner AA, 
Desrosiers RC. Resistance of neonatal monkeys 
to live attenuated vaccine strains of simian 
immunodeficiency virus. Nat Med. 1997;3:32-6.  
37.  Mariani R, Kirchhoff F, Greenough TC, 
Sullivan JL, Desrosiers RC, Skowronski J. High 
frequency of defective nef alleles in a long-term 
survivor with nonprogressive human 
immunodeficiency virus type 1 infection.  J 
Virol.1996; 70:7752-64.   
38.  Wyand MS, Manson KH, Garcia-Moll M, 
Montefiori D, Desrosiers RC. Vaccine protection by 
a triple deletion mutant of simian 
immunodeficiency virus. J Virol. 1996; 70: 3724-
33.  
39.  Bagasra O.  A unified concept of HIV-1 
latency. Expert Opin Biol Ther 2006; 6: 1135-
1149.   
40.  Wikipedia, Kary Mullis’s personal website: 
http://en.wikipedia.org/wiki/Kary_Mullis 
Page 62